Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab

被引：0
|
作者：
Khan, M. [1 ]
Heetun, Z. [1 ]
Moloney, J. [1 ]
Courtney, G. [1 ]
Aftab, A. R. [1 ]
机构：
[1] St Lukes Hosp, Kilkenny, Kilkenny, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5 (14S114)
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [21] Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease
    Buffone, Elisa
    Gupta, Shaan
    Al Ibrahim, Bashaar
    Marshall, John K.
    Halder, Smita
    Tse, Frances
    Albashir, Siwar
    Morgan, David
    Lumb, Barry
    Armstrong, David
    Narula, Neeraj
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2022, 56 (09) : 794 - 797
  • [22] Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implications
    Cortes, X.
    Moles, J. R.
    Fernandez, S.
    Clofent, J.
    Moreno, M.
    Rodriguez, J.
    Primo, J.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S355 - S356
  • [23] Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
    Petric, Zvonimir
    Goncalves, Joao
    Paixao, Paulo
    PHARMACEUTICS, 2022, 14 (09)
  • [24] Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab
    Sed, N. Piazza O.
    Maregatti, M. C.
    Pessarelli, T.
    Vigano, C.
    Conforti, F.
    Noviello, D.
    Bezzio, C.
    Amoroso, C.
    Molteni, C.
    Anolli, M. P.
    Pirola, L.
    Saibeni, S.
    Fraquelli, M.
    Vecchi, M.
    Caprioli, F.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1669 - I1669
  • [25] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Mayte Gil-Candel
    Juan José Gascón-Cánovas
    Elena Urbieta-Sanz
    Lorena Rentero-Redondo
    María Onteniente-Candela
    Carles Iniesta-Navalón
    International Journal of Clinical Pharmacy, 2020, 42 : 500 - 507
  • [26] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Gil-Candel, Mayte
    Gascon-Canovas, Juan Jose
    Urbieta-Sanz, Elena
    Rentero-Redondo, Lorena
    Onteniente-Candela, Maria
    Iniesta-Navalon, Carles
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (02) : 500 - 507
  • [27] Uptake of drug monitoring of infliximab and adalimumab in inflammatory bowel disease in Australia
    Janko, N.
    Little, R. D.
    Sparrow, M. P.
    Gibson, P. R.
    Ward, M. G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 136 - 137
  • [28] Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease
    Munoz Villafranca, M. D. C.
    Merino, O.
    Gomez, L.
    Higuera, R. O.
    Arreba, P.
    Nagore, D.
    Ruiz-Arguello, B.
    Gorostiza, I.
    Lopez, M. L.
    Ortiz de Zarate, J.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1570 - I1570
  • [29] NUTRITIONAL STATUS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION
    Kusunoki, Ryusaku
    Kuwai, Toshio
    Kato, Naohiro
    Sugata, Shuhei
    Hamada, Takuro
    Furuya, Nao
    Mizumoto, Takeshi
    Tamaru, Yuzuru
    Yamaguchi, Atsushi
    Kouno, Hirotaka
    Kohno, Hiroshi
    GASTROENTEROLOGY, 2023, 164 (06) : S709 - S709
  • [30] Autonomic Dysfunctions in Patients with Inflammatory Bowel Disease in Clinical Remission
    Purnima Sharma
    Govind K. Makharia
    Vineet Ahuja
    Sada Nand Dwivedi
    Kishore Kumar Deepak
    Digestive Diseases and Sciences, 2009, 54 : 853 - 861
12345